GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

51

FIT Plus Calprotectin Improves Young-Onset GI Triage : Gut | May 2026

Introduction Inflammatory Bowel Disease and early-onset Colorectal Cancer are increasingly encountered in younger adults presenting with lower gastrointestinal symptoms. However, distinguishing inflammatory disease from neoplasia in this age...

52

Upadacitinib–Vedolizumab Combination Breaks the UC Efficacy Ceiling : Gastroenterology | May 2026

Introduction Ulcerative Colitis treatment outcomes remain constrained by an “efficacy ceiling,” with most advanced therapies achieving endoscopic remission rates below 30%. Rapid induction of deep remission remains a...

53

AI and Multi-Omics Redefine Postoperative Crohn’s Recurrence : Gut | May 2026

Introduction Crohn's Disease postoperative recurrence remains one of the greatest long-term challenges after intestinal resection, with endoscopic recurrence developing in a substantial proportion of patients within the first...

54

International Consensus Defines the Role of Intestinal Ultrasound in Postoperative Crohn’s Disease Surveillance : Lancet Gastroenterol Hepatol | May 2026

Introduction Crohn's Disease recurrence after ileocolic resection remains common, with postoperative endoscopic recurrence often preceding clinical symptoms. Early identification of recurrence is critical because timely therapeutic escalation may...

55

Real-World Risankizumab Outcomes in Refractory CD : Frontline Gastroenterol | May 2026

Introduction Risankizumab is a selective interleukin-23 p19 inhibitor approved for moderate-to-severe Crohn’s Disease following strong efficacy signals in phase III trials. However, real-world evidence in heavily pretreated Crohn’s...

56

Upadacitinib Shows Real-World Benefit in Perianal Crohn’s Disease : Clin Gastroenterol Hepatol | May 2026

Introduction Perianal Crohn’s Disease remains one of the most disabling and treatment-refractory manifestations of inflammatory bowel disease, frequently associated with fistulas, abscesses, recurrent surgery and impaired quality of...

57

FIT Pathways Frequently Identify IBD in Younger Patients : Br J Surg | May 2026

Introduction Inflammatory bowel disease and Colorectal Cancer frequently present with overlapping lower gastrointestinal symptoms including rectal bleeding, altered bowel habits and abdominal pain. In the UK, symptomatic Faecal...

58

Upadacitinib in Perianal Crohn’s Disease: CGH | May 2026

Introduction Perianal Crohn’s disease (pCD) remains one of the most challenging manifestations of inflammatory bowel disease, often associated with fistulas, recurrent infections, impaired quality of life, and repeated...

59

Vaccination Uptake Remains Poor in Immunosuppressed IBD Patients : Frontline Gastroenterol | May 2026

Introduction Inflammatory bowel disease patients receiving immunosuppressive therapy are at increased risk of vaccine-preventable infections, including influenza, pneumococcal disease and COVID-19. International guidelines strongly recommend routine immunization in...

60

A Pragmatic Prevention Framework for IBD in the Global South : Gut | 2026

Introduction Inflammatory bowel disease is rapidly emerging as a global disease, with rising incidence across low-income and middle-income countries. Although biologics and small-molecule therapies have transformed disease outcomes,...

Previous
156713
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer